159 related articles for article (PubMed ID: 38539572)
1. Long-Term Follow-Up Outcomes in Women with In Situ/Microinvasive Adenocarcinoma of the Uterine Cervix Undergoing Conservative Treatment-Cervical Adenocarcinoma Study Group Italian Society of Colposcopy and Cervico-Vaginal Pathology.
Giannella L; Delli Carpini G; Di Giuseppe J; Grelloni C; Bogani G; Dri M; Sopracordevole F; Clemente N; Giorda G; De Vincenzo R; Evangelista MT; Gardella B; Dominoni M; Monti E; Alessi C; Alessandrini L; Guerriero A; Pagan A; Caretto M; Ghelardi A; Amadori A; Origoni M; Barbero M; Raspagliesi F; Simoncini T; Vercellini P; Spinillo A; Scambia G; Ciavattini A
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539572
[TBL] [Abstract][Full Text] [Related]
2. HPV testing as an effective triage strategy in the follow-up after fertility-sparing treatment for glandular lesions of the uterine cervix.
Dostalek L; Freitag P; Slovackova M; Zima T; Komarc M; Fricova L; Fucik T; Nemejcova K; Cibula D; Brynda D; Slama J
Int J Gynecol Cancer; 2023 Dec; ():. PubMed ID: 38054269
[TBL] [Abstract][Full Text] [Related]
3. In Situ/Microinvasive Adenocarcinoma of the Uterine Cervix and HPV-Type Impact: Pathologic Features, Treatment Options, and Follow-Up Outcomes-Cervical Adenocarcinoma Study Group (CAS-Group).
Giannella L; Delli Carpini G; Di Giuseppe J; Bogani G; Sopracordevole F; Clemente N; Giorda G; De Vincenzo RP; Evangelista MT; Gardella B; Dominoni M; Monti E; Alessi C; Alessandrini L; Pagan A; Caretto M; Ghelardi A; Amadori A; Origoni M; Barbero M; Raspagliesi F; Simoncini T; Vercellini P; Scambia G; Ciavattini A
Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296839
[TBL] [Abstract][Full Text] [Related]
4. Human papillomavirus (HPV) test and PAP smear as predictors of outcome in conservatively treated adenocarcinoma in situ (AIS) of the uterine cervix.
Costa S; Negri G; Sideri M; Santini D; Martinelli G; Venturoli S; Pelusi C; Syrjanen S; Syrjanen K; Pelusi G
Gynecol Oncol; 2007 Jul; 106(1):170-6. PubMed ID: 17481701
[TBL] [Abstract][Full Text] [Related]
5. Factors predicting the outcome of conservatively treated adenocarcinoma in situ of the uterine cervix: an analysis of 166 cases.
Costa S; Venturoli S; Negri G; Sideri M; Preti M; Pesaresi M; Falasca A; Barbieri D; Zerbini M; Santini D; Sandri MT; Ghiringhello B; Caroppo Venturini N; Syrjänen S; Syrjänen K
Gynecol Oncol; 2012 Mar; 124(3):490-5. PubMed ID: 22188786
[TBL] [Abstract][Full Text] [Related]
6. Performance of HPV DNA testing in the follow-up after treatment of high-grade cervical lesions, adenocarcinoma in situ (AIS) and microinvasive carcinoma.
Costa S; Venturoli S; Origoni M; Preti M; Mariani L; Cristoforoni P; Sandri MT
Ecancermedicalscience; 2015; 9():528. PubMed ID: 25987897
[TBL] [Abstract][Full Text] [Related]
7. Human papillomavirus DNA in adenocarcinoma in situ, microinvasive adenocarcinoma of the uterine cervix, and coexisting cervical squamous intraepithelial neoplasia.
Tase T; Okagaki T; Clark BA; Twiggs LB; Ostrow RS; Faras AJ
Int J Gynecol Pathol; 1989; 8(1):8-17. PubMed ID: 2540102
[TBL] [Abstract][Full Text] [Related]
8. Predictors of treatment failure for adenocarcinoma
Belkić K; Andersson S; Alder S; Mints M; Megyessi D
Oncol Lett; 2022 Oct; 24(4):357. PubMed ID: 36168314
[TBL] [Abstract][Full Text] [Related]
9. The relationship of human papillomavirus infection with endocervical glandular involvement on cone specimens in women with cervical intraepithelial neoplasia.
Spinillo A; Dominoni M; Boschi AC; Cesari S; Fiandrino G; Gardella B
Gynecol Oncol; 2020 Dec; 159(3):630-635. PubMed ID: 33041069
[TBL] [Abstract][Full Text] [Related]
10. Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation.
Verguts J; Bronselaer B; Donders G; Arbyn M; Van Eldere J; Drijkoningen M; Poppe W
BJOG; 2006 Nov; 113(11):1303-7. PubMed ID: 16978225
[TBL] [Abstract][Full Text] [Related]
11. Value of endocervical margin and high-risk human papillomavirus status after conization for high-grade cervical intraepithelial neoplasia, adenocarcinoma in situ, and microinvasive carcinoma of the uterine cervix.
Kong TW; Son JH; Chang SJ; Paek J; Lee Y; Ryu HS
Gynecol Oncol; 2014 Dec; 135(3):468-73. PubMed ID: 25284039
[TBL] [Abstract][Full Text] [Related]
12. Optimising follow-up strategy based on cytology and human papillomavirus after fertility-sparing surgery for early stage cervical cancer: a nationwide, population-based, retrospective cohort study.
Schuurman TN; Schaafsma M; To KH; Verhoef VMJ; Sikorska K; Siebers AG; Wenzel HHB; Bleeker MCG; Roes EM; Zweemer RP; de Vos van Steenwijk PJ; Yigit R; Beltman JJ; Zusterzeel PLM; Lok CAR; Bekkers RLM; Mom CH; van Trommel NE
Lancet Oncol; 2023 Dec; 24(12):1349-1358. PubMed ID: 37952541
[TBL] [Abstract][Full Text] [Related]
13. [Analysis of recurrence and its influencing factors in patients with cervical HSIL within 24 months after LEEP].
Chen LM; Liu L; Tao X; He Y; Guo LP; Zhang HW; Zhou XR; Sui L
Zhonghua Fu Chan Ke Za Zhi; 2019 Aug; 54(8):534-540. PubMed ID: 31461810
[No Abstract] [Full Text] [Related]
14. High-risk HPV testing in women with borderline and mild dyskaryosis: long-term follow-up data and clinical relevance.
Denise Zielinski G; Snijders PJ; Rozendaal L; Voorhorst FJ; Runsink AP; de Schipper FA; Meijer CJ
J Pathol; 2001 Oct; 195(3):300-6. PubMed ID: 11673826
[TBL] [Abstract][Full Text] [Related]
15. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
16. Human papillomavirus DNA in glandular dysplasia and microglandular hyperplasia: presumed precursors of adenocarcinoma of the uterine cervix.
Tase T; Okagaki T; Clark BA; Twiggs LB; Ostrow RS; Faras AJ
Obstet Gynecol; 1989 Jun; 73(6):1005-8. PubMed ID: 2542853
[TBL] [Abstract][Full Text] [Related]
17. Outcome and associated factors of high-risk human papillomavirus infection without cervical lesions.
Feng T; Cheng B; Sun W; Yang Y
BMC Womens Health; 2023 Nov; 23(1):599. PubMed ID: 37957634
[TBL] [Abstract][Full Text] [Related]
18. Is conservative treatment for adenocarcinoma in situ of the cervix safe?
Soutter WP; Haidopoulos D; Gornall RJ; McIndoe GA; Fox J; Mason WP; Flanagan A; Nicholas N; Barker F; Abrahams J; Lampert I; Sarhanis P
BJOG; 2001 Nov; 108(11):1184-9. PubMed ID: 11762660
[TBL] [Abstract][Full Text] [Related]
19. The impact of HPV-specific infection in women diagnosed with atypical glandular cells: Results from the HPV-AGC study.
Bogani G; Sopracordevole F; Casarin J; Pinelli C; Leone Roberti Maggiore U; Brusadelli C; Guerrisi R; Ditto A; Dell'Acqua A; Serati M; Lopez S; Ferrero S; Ghezzi F; Raspagliesi F
Pathol Res Pract; 2020 Nov; 216(11):153184. PubMed ID: 32916447
[TBL] [Abstract][Full Text] [Related]
20. Survival of women with microinvasive adenocarcinoma of the cervix is not improved by radical surgery.
Bean LM; Ward KK; Plaxe SC; McHale MT
Am J Obstet Gynecol; 2017 Sep; 217(3):332.e1-332.e6. PubMed ID: 28522318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
